JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by CTLA ‐4 and PD ‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report
Cancer Reports · 2024-10 · 7 (10)
DOI: 10.1002/cnr2.70032 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cancer Reports, online erschienen am 28.10.2024. Verfasst von Masashi Kono und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Heterocyclic Compounds, 3-Ring, Antineoplastic Combined Chemotherapy Protocols, Mesothelioma, Malignant. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors have demonstrated efficacy against various cancers; however, there is a rising incidence of immune‐related colitis. Some cases of immune‐related colitis prove resistant to treatment, even with the administration of glucocorticoids or infliximab, and there is currently no established standard treatment for such cases. Case The patient, a 73‐year‐old male, had undergone combination therapy for malignant pleural mesothelioma for 2 years, utilizing both ipilimumab (a CTLA‐4 inhibitor) and nivolumab (a PD‐1 inhibitor). Unfortunately, the treatment led to side effects, specifically immune‐related adverse event (irAE) enterocolitis. Steroid and infliximab treatment failed to improve the patient's condition. Treatment with tacrolimus was attempted, but the patient remained unresponsive. Subsequently, 45 mg of upadacitinib, a Janus kinase (JAK) inhibitor, was administered. Symptoms improved rapidly following upadacitinib administration, and endoscopy also revealed positive results. With the increasing incidence of immune‐related colitis, some patients have become resistant to treatment with glucocorticoids and infliximab. In this case, the irAE enterocolitis was improved by upadacitinib administration.
Conclusion
In cases where immune‐related colitis proves resistant to treatment with glucocorticoids, infliximab, or tacrolimus, upadacitinib represents a potential option as a JAK inhibitor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
- Department of Gastroenterology, Red Cross Hospital, Athens, Greece.
ORCID-Profile: Yoriaki Komeda, Satoru Hagiwara
Zitieren
APA
Kono, M., Komeda, Y., Kawakami, H., Hagiwara, S., Tribonias, G., Handa, K., Omoto, S., Takenaka, M., Kashida, H., Tsuji, N., & Kudo, M. (2024). JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by CTLA ‐4 and PD ‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report. Cancer Reports, 7(10). https://doi.org/10.1002/cnr2.70032
Vancouver
Kono M, Komeda Y, Kawakami H, Hagiwara S, Tribonias G, Handa K, et al. JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by CTLA ‐4 and PD ‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report. Cancer Reports. 2024;7(10). doi:10.1002/cnr2.70032
BibTeX
@article{Kono2024,
author = {Kono, Masashi and Komeda, Yoriaki and Kawakami, Hisato and Hagiwara, Satoru and Tribonias, George and Handa, Kohei and Omoto, Shunsuke and Takenaka, Mamoru and Kashida, Hiroshi and Tsuji, Naoko and Kudo, Masatoshi},
title = {JAK Inhibitor Upadacitinib Induces Remission in Refractory Immune‐Related Colitis Triggered by CTLA ‐4 and PD ‐1 Inhibitor Combination Therapy in Malignant Pleural Mesothelioma: A Case Report},
journal = {Cancer Reports},
year = {2024},
volume = {7},
number = {10},
doi = {10.1002/cnr2.70032}
}
EUVIMED